Bioxyne Ltd

Consumer Defensive AU BXN

0.028AUD
-0.001(3.45%)

Last update at 2025-01-21T05:10:00Z

Day Range

0.030.03
LowHigh

52 Week Range

0.0040.03
LowHigh

Fundamentals

  • Previous Close 0.03
  • Market Cap57.38M
  • Volume922195
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-1.08218M
  • Revenue TTM9.64M
  • Revenue Per Share TTM0.005
  • Gross Profit TTM 3.72M
  • Diluted EPS TTM-0.01

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -1.96444M -0.23651M -0.42573M -0.59310M -1.36588M
Minority interest - - 0.05M 0.05M 0.05M
Net income -1.96444M -0.23651M -0.42573M -0.59310M -1.13989M
Selling general administrative 2.59M 0.88M 0.83M 0.88M 1.06M
Selling and marketing expenses 0.19M 0.02M 0.04M 0.04M 0.07M
Gross profit 1.90M 1.29M 1.08M 1.22M 1.14M
Reconciled depreciation 0.09M 0.05M 0.05M 0.07M 0.02M
Ebit -2.04243M -0.15332M -0.26962M -0.37360M -1.59187M
Ebitda -1.95584M -0.10327M -0.21972M -0.30179M -1.57280M
Depreciation and amortization 0.09M 0.05M 0.05M 0.07M 0.02M
Non operating income net other - - - - -
Operating income -1.83573M -0.45306M -0.37412M -0.31222M -1.59187M
Other operating expenses 7.27M 0.96M 2.72M 2.96M 3.71M
Interest expense 0.00058M 0.00058M 0.00168M 0.00703M 0.00703M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.00257M 0.02M 0.02M 0.06M 0.14M
Net interest income 0.00257M 0.01M 0.02M 0.03M 0.04M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.00715M 0.04M 0.06M 0.11M -0.22599M
Total revenue 5.16M 2.42M 2.11M 2.26M 2.13M
Total operating expenses 4.04M 1.50M 1.43M 1.73M 2.72M
Cost of revenue 3.26M 1.13M 1.03M 1.04M 0.99M
Total other income expense net 0.09M -0.04376M -0.09470M -0.11193M 0.23M
Discontinued operations - - - - -
Net income from continuing ops -1.96444M -0.23651M -0.42573M -0.59310M -1.26588M
Net income applicable to common shares -1.96444M -0.23651M -0.49573M -0.59310M -1.26588M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 6.70M 17.69M 2.92M 2.75M 3.34M
Intangible assets - 0.03M 0.03M 0.03M 0.03M
Earning assets - - - - -
Other current assets 0.76M 0.07M 0.07M 0.05M 0.24M
Total liab 3.40M 2.69M 0.98M 0.74M 0.73M
Total stockholder equity 3.61M 15.14M 1.89M 1.95M 2.56M
Deferred long term liab - - - - -
Other current liab 1.49M 1.48M 0.89M 0.57M 0.51M
Common stock 19.00M 17.55M 62.18M 62.18M 62.18M
Capital stock - 17.55M 62.18M 62.18M 62.18M
Retained earnings -15.59547M -2.48375M -60.47733M -60.17083M -59.74510M
Other liab - - -0.00472M - -
Good will - 11.57M 11.57M - -
Other assets 0.00000M - - - -
Cash 1.03M 3.85M 2.17M 1.60M 1.75M
Cash and equivalents - - - - -
Total current liabilities 2.91M 2.69M 0.98M 0.74M 0.73M
Current deferred revenue 0.04M - - -0.04746M -0.48589M
Net debt -0.35427M -3.84597M -2.16801M -1.55475M -1.70042M
Short term debt 0.18M 0.00000M 0.00000M 0.05M 0.05M
Short long term debt - - - - -
Short long term debt total 0.67M - - 0.05M 0.05M
Other stockholder equity - -15.06400M 0.19M -1.93671M -2.43243M
Property plant equipment - 0.09M 0.07M 0.09M 0.17M
Total current assets 5.59M 6.04M 2.82M 2.58M 3.07M
Long term investments - - - - -
Net tangible assets - 3.57M 1.86M 1.81M 2.46M
Short term investments - - - - -
Net receivables 1.66M 0.90M 0.02M 0.34M 0.30M
Long term debt - - - - -
Inventory 2.14M 0.99M 0.31M 0.44M 0.77M
Accounts payable 1.19M 1.21M 0.10M 0.18M 0.66M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.20M 0.07M 0.19M -0.05575M 0.12M
Additional paid in capital - - - - -
Common stock total equity - - - - 62.18M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.29M -11.65303M - -0.16816M -0.26514M
Deferred long term asset charges - - - - -
Non current assets total 1.11M 11.65M 0.10M 0.17M 0.27M
Capital lease obligations - - - - 0.05M
Long term debt total - 0.00000M 0.00000M 0.00000M 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments 3.56M -0.00579M - -0.03366M -0.17236M
Change to liabilities 1.81M 0.24M 0.02M -0.15066M 0.10M
Total cashflows from investing activities 3.56M -0.00579M -0.00579M -0.03366M -0.17236M
Net borrowings 0.37M 0.49M -0.04678M -0.05233M -0.05233M
Total cash from financing activities 1.35M -0.04678M -0.04678M -0.05233M -0.05233M
Change to operating activities - - - - -
Net income -1.93997M -0.49402M -0.49573M -0.59310M -1.26588M
Change in cash 3.78M 0.57M -0.14568M -0.02002M -1.54200M
Begin period cash flow 0.07M 1.60M 1.75M 1.77M 3.31M
End period cash flow 3.85M 2.17M 1.60M 1.75M 1.77M
Total cash from operating activities -0.84128M -0.50681M 0.05M 0.05M -1.33804M
Issuance of capital stock 0.58M - - - -
Depreciation 0.11M 0.03M 0.07M 0.10M 0.02M
Other cashflows from investing activities 3.62M 0.09M - 0.00000M -0.10870M
Dividends paid - - - - -
Change to inventory -0.91926M -0.07555M 0.40M -0.05432M -0.08494M
Change to account receivables -0.59549M -0.26558M 0.02M 0.48M -0.24190M
Sale purchase of stock 0.58M 0.00000M - - 0.00000M
Other cashflows from financing activities 0.77M -0.04678M -0.04678M -0.05233M -0.05233M
Change to netincome 0.70M 0.13M 0.03M 0.17M 0.04M
Capital expenditures 0.06M 0.00579M 0.03M 0.03M 0.06M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -1.51475M -0.34113M 0.41M 0.43M 0.23M
Stock based compensation 0.70M 0.10M - - -
Other non cash items 0.99M -0.04351M 0.07M 0.12M 1.27M
Free cash flow -0.89992M -0.51260M 0.02M 0.01M -1.40170M

Peer Comparison

Sector: Consumer Defensive Industry: Packaged Foods

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BXN
Bioxyne Ltd
-0.001 3.45% 0.03 - - 5.95 16.48 6.33 -54.5809
A2M
A2 Milk Company Ltd
-0.03 0.51% 5.84 27.14 25.38 2.47 3.59 2.18 13.32
BGA
Bega Cheese Ltd
0.06 1.05% 5.76 56.30 32.57 0.49 1.68 0.58 13.58
CBO
Cobram Estate Olives Ltd
- -% 2.05 52.00 - 3.82 2.68 4.75 16.25
RIC
Ridley Corporation Ltd
0.03 1.11% 2.73 22.50 15.50 0.68 2.64 0.73 10.12

Reports Covered

Stock Research & News

Profile

Bioxyne Limited, a life sciences and consumer health products company, engages in the manufacture and distribution of consumer health products, patented probiotics, health supplements, therapeutic goods, and alternative medicines. The company manufactures, commercializes, and distributes plant-based wellness products and supplements, including cannabinoids, cannabis extracts, cannabis pastilles, THC flowers, vapes, oral liquids, nootropic and skin care products, and mushroom complexes. It also develops various functional food products, such as lactobacillus fermentum VRI-003 for over-the counter gut health immune supplement products. In addition, the company provides product research and development services, and telemedicine services. Further, it operates BLS Clinics, a telehealth platform; and CanXChange Australia, a machine-learning driven B2B technology platform for sponsors, manufacturers, cultivators, and pharmacies to interact, manage chain of custody, and buy and sell bulk starting materials, APIs, and finished products in a regulated environment. The company offers its products under the Dr Watson, Mirai Solution, and Apothecary CBD brands. It provides its products online, as well as through wholesale and direct sales in Australia, the United States, the United Kingdom, Japan, Czechia, Switzerland, France, and Germany. The company was incorporated in 1998 and is headquartered in Sydney, Australia.

Bioxyne Ltd

50 Clarence Street, Sydney, NSW, Australia, 2000

Key Executives

Name Title Year Born
Mr. Nam Hoat Chua B.A., BA MD, CEO & Director NA
Mr. Guy Adrian Robertson B.Com., B.Comm(Hons.), C.A., CA, MAICD CFO, Company Sec. & Exec. Director 1954
Ms. Rachel Qian Financial Controller & Assistant Company Sec. NA
Mr. Samuel Watson CEO, MD & Executive Director NA
Mr. Guy Adrian Robertson B.Com., B.Comm(Hons.), CA, MAICD CFO & Company Secretary 1953
Mr. Jason Hine COO & Executive Director NA
Ms. Rachel Qian Financial Controller & Assistant Company Secretary NA
Mr. Samuel Watson CEO, MD & Executive Director NA
Mr. Guy Adrian Robertson B.Com., B.Comm(Hons.), CA, MAICD CFO & Company Secretary 1953
Mr. Jason Hine COO & Executive Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.